Skip to main content
Erschienen in: Heart and Vessels 7/2023

16.02.2023 | Original Article

The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension

verfasst von: Woo Jin Ahn, Seung-Woon Rha, Byoung Geol Choi, Myung Ho Jeong, and Other Korea Acute Myocardial Infarction Registry (KAMIR)-National Institutes of Health (NIH) Investigators

Erschienen in: Heart and Vessels | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to investigate the impact of angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on 3-year clinical outcomes in elderly (≥ 65) acute myocardial infarction (AMI) patients without a history of hypertension who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES).

Methods

A total of 13,104 AMI patients who were registered in the Korea AMI registry (KAMIR)-National Institutes of Health (NIH) were included in the study. The primary endpoint was 3-year major adverse cardiac events (MACE), which was defined as the composite of all-cause death, recurrent myocardial infarction (MI), and any repeat revascularization. To adjust baseline potential confounders, an inverse probability weighting (IPTW) analysis was performed.

Results

The patients were divided into two groups: the ACEI group, n = 872 patients and the ARB group, n = 508 patients. After IPTW matching, baseline characteristics were balanced. During the 3-year clinical follow-up, the incidence of MACE was not different between the two groups. However, incidence of stroke (hazard ratio [HR], 0.375; 95% confidence interval [CI], 0.166–0.846; p = 0.018) and re-hospitalization due to heart failure (HF) (HR, 0.528; 95% CI, 0.289–0.965; p = 0.038) in the ACEI group were significantly lower than in the ARB group.

Conclusion

In elderly AMI patients who underwent PCI with DES without a history of hypertension, the use of ACEI was significantly associated with reduced incidences of stroke, and re-hospitalization due to HF than those with the use of ARB.
Literatur
1.
Zurück zum Zitat Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U (2010) The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 96:604–609CrossRefPubMed Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U (2010) The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 96:604–609CrossRefPubMed
2.
Zurück zum Zitat Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferrieres J, Schiele F, Simon T, Danchin N, Puymirat E, investigators F-M, (2019) Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: the FAST-MI 2010 registry. Eur J Prev Cardiol 26:411–419CrossRefPubMed Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferrieres J, Schiele F, Simon T, Danchin N, Puymirat E, investigators F-M, (2019) Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: the FAST-MI 2010 registry. Eur J Prev Cardiol 26:411–419CrossRefPubMed
3.
Zurück zum Zitat Messerli FH, Bangalore S (2017) Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation 135:2085–2087CrossRefPubMed Messerli FH, Bangalore S (2017) Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation 135:2085–2087CrossRefPubMed
4.
Zurück zum Zitat Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177CrossRefPubMed Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177CrossRefPubMed
5.
Zurück zum Zitat Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315CrossRefPubMed Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315CrossRefPubMed
6.
Zurück zum Zitat Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153CrossRefPubMed Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153CrossRefPubMed
7.
Zurück zum Zitat Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677CrossRefPubMed Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327:669–677CrossRefPubMed
8.
Zurück zum Zitat Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906CrossRefPubMed Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906CrossRefPubMed
9.
Zurück zum Zitat McAlister FA (2012) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 33:505–514CrossRefPubMed McAlister FA (2012) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. Eur Heart J 33:505–514CrossRefPubMed
10.
Zurück zum Zitat McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 47:726–733CrossRefPubMed McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M (2006) The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 47:726–733CrossRefPubMed
11.
Zurück zum Zitat Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E (1999) Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens 12:665–672CrossRefPubMed Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E (1999) Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of myocardial infarction long-term evaluation. Am J Hypertens 12:665–672CrossRefPubMed
12.
Zurück zum Zitat Gustafsson F, Torp-Pedersen C, Køber L, Hildebrandt P (1997) Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE study group. Trandolapril Cardiac Event J Hypertens 15:793–798PubMed Gustafsson F, Torp-Pedersen C, Køber L, Hildebrandt P (1997) Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE study group. Trandolapril Cardiac Event J Hypertens 15:793–798PubMed
13.
Zurück zum Zitat Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952CrossRefPubMed Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952CrossRefPubMed
14.
Zurück zum Zitat Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA (2011) Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305:913–922CrossRefPubMedPubMedCentral Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA (2011) Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305:913–922CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Choi SY, Choi BG, Rha SW, Byun JK, Shim MS, Li H, Mashaly A, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH (2017) Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention. Int J Cardiol 249:48–54CrossRefPubMed Choi SY, Choi BG, Rha SW, Byun JK, Shim MS, Li H, Mashaly A, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH (2017) Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention. Int J Cardiol 249:48–54CrossRefPubMed
16.
Zurück zum Zitat Byun JK, Choi BG, Rha SW, Choi SY, Jeong MH (2018) Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. Atherosclerosis 277:130–135CrossRefPubMed Byun JK, Choi BG, Rha SW, Choi SY, Jeong MH (2018) Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. Atherosclerosis 277:130–135CrossRefPubMed
18.
Zurück zum Zitat O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:485–510CrossRefPubMed O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:485–510CrossRefPubMed
19.
Zurück zum Zitat Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Zidar JP (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57:e215-367CrossRefPubMed Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Zidar JP (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57:e215-367CrossRefPubMed
20.
Zurück zum Zitat Tseng DS, Kwong J, Rezvani F, Coates AO (2010) Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 123:183.e11–15CrossRefPubMed Tseng DS, Kwong J, Rezvani F, Coates AO (2010) Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 123:183.e11–15CrossRefPubMed
21.
Zurück zum Zitat Hara M, Sakata Y, Nakatani D, Suna S, Usami M, Matsumoto S, Sugitani T, Nishino M, Sato H, Kitamura T, Nanto S, Hamasaki T, Hori M, Komuro I (2014) Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Am J Cardiol 114:1–8CrossRefPubMed Hara M, Sakata Y, Nakatani D, Suna S, Usami M, Matsumoto S, Sugitani T, Nishino M, Sato H, Kitamura T, Nanto S, Hamasaki T, Hori M, Komuro I (2014) Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Am J Cardiol 114:1–8CrossRefPubMed
22.
Zurück zum Zitat Her AY, Choi BG, Rha SW, Kim YH, Choi CU, Jeong MH (2020) The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. PLoS ONE 15:e0242314CrossRefPubMedPubMedCentral Her AY, Choi BG, Rha SW, Kim YH, Choi CU, Jeong MH (2020) The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. PLoS ONE 15:e0242314CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bloom DE, Boersch-Supan A, McGee P, Seike A (2011) Population aging: facts, challenges, and responses. Benefits Compens Int 41:22 Bloom DE, Boersch-Supan A, McGee P, Seike A (2011) Population aging: facts, challenges, and responses. Benefits Compens Int 41:22
25.
Zurück zum Zitat Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y (2020) Comparison of clinical outcomes between angiotensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation. Anatol J Cardiol 23:86–98PubMedPubMedCentral Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y (2020) Comparison of clinical outcomes between angiotensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation. Anatol J Cardiol 23:86–98PubMedPubMedCentral
26.
Zurück zum Zitat Strauss MH, Hall AS (2006) Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114:838–854CrossRefPubMed Strauss MH, Hall AS (2006) Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114:838–854CrossRefPubMed
27.
Zurück zum Zitat Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788CrossRefPubMed Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788CrossRefPubMed
28.
Zurück zum Zitat McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG (2004) Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 351:2795–2804CrossRefPubMed McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG (2004) Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 351:2795–2804CrossRefPubMed
29.
Zurück zum Zitat Yusuf S, Pogue J (2005) ACE inhibition in stable coronary artery disease. N Engl J Med 352:937–939CrossRefPubMed Yusuf S, Pogue J (2005) ACE inhibition in stable coronary artery disease. N Engl J Med 352:937–939CrossRefPubMed
Metadaten
Titel
The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension
verfasst von
Woo Jin Ahn
Seung-Woon Rha
Byoung Geol Choi
Myung Ho Jeong
and Other Korea Acute Myocardial Infarction Registry (KAMIR)-National Institutes of Health (NIH) Investigators
Publikationsdatum
16.02.2023
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 7/2023
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-023-02244-x

Weitere Artikel der Ausgabe 7/2023

Heart and Vessels 7/2023 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.